{"id":29643,"date":"2022-01-31T09:14:08","date_gmt":"2022-01-31T08:14:08","guid":{"rendered":"https:\/\/eurogip.fr\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/"},"modified":"2022-01-31T09:14:08","modified_gmt":"2022-01-31T08:14:08","slug":"the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health","status":"publish","type":"post","link":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/","title":{"rendered":"The CJEU confirms the identification of BPA as an endocrine disruptor for health"},"content":{"rendered":"<p>The Court of Justice of the European Union (CJEU) has confirmed on appeal the identification of bisphenol A (BPA) as a substance of very high concern(1) for its endocrine disrupting properties for human health.<\/p>\n<p>It has indeed rejected the appeal of the European Plastics Manufacturers&#8217; Association, PlasticsEurope against the judgment of the General Court of the European Union of 20 September 2019, PlasticsEurope\/ECHA (T-636\/17) in a judgment of 21 December 2021. The European Chemicals Agency (ECHA) had included BPA on the list of candidate substances for authorisation due to its endocrine disrupting properties and potential serious health effects, which the judgment confirms.<\/p>\n<p>As a reminder, PlasticsEurope brought three cases before the European Court of Justice concerning the three hazardous properties of bisphenol A: reproductive toxicity (case T-185\/17), endocrine disruptor for human health (case C-876\/19 P), and endocrine disruptor for the environment. The first two cases have now been closed with the appeal confirming the correctness of the ECHA decisions. The third is still pending.<\/p>\n<p>(1) Substance of Very High Concern (SVHC) as defined in Regulation 1907\/2006 (REACH)<\/p>\n<p><a href=\"https:\/\/curia.europa.eu\/juris\/document\/document.jsf?docid=251521&amp;text=&amp;dir=&amp;doclang=EN&amp;part=1&amp;occ=first&amp;mode=DOC&amp;pageIndex=0&amp;cid=3065093\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline;\">Judgment of the Court of Justice<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Court of Justice of the European Union (CJEU) has confirmed on appeal the identification of bisphenol A (BPA) as a substance of very high concern for its endocrine disrupting properties for human health.<\/p>\n","protected":false},"author":4,"featured_media":29574,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[907],"class_list":["post-29643","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-community-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The CJEU confirms the identification of BPA as an endocrine disruptor for health - Eurogip<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The CJEU confirms the identification of BPA as an endocrine disruptor for health - Eurogip\" \/>\n<meta property=\"og:description\" content=\"The Court of Justice of the European Union (CJEU) has confirmed on appeal the identification of bisphenol A (BPA) as a substance of very high concern for its endocrine disrupting properties for human health.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/\" \/>\n<meta property=\"og:site_name\" content=\"Eurogip\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-31T08:14:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/eurogip.fr\/wp-content\/uploads\/2022\/01\/bottle-1811019_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1917\" \/>\n\t<meta property=\"og:image:height\" content=\"1033\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Isabelle Leleu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Isabelle Leleu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/\"},\"author\":{\"name\":\"Isabelle Leleu\",\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/#\\\/schema\\\/person\\\/ecf33c1b8323512588da2815912dafbd\"},\"headline\":\"The CJEU confirms the identification of BPA as an endocrine disruptor for health\",\"datePublished\":\"2022-01-31T08:14:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/\"},\"wordCount\":191,\"image\":{\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/eurogip.fr\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/bottle-1811019_1920.jpg\",\"articleSection\":[\"Community news\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/\",\"url\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/\",\"name\":\"The CJEU confirms the identification of BPA as an endocrine disruptor for health - Eurogip\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/eurogip.fr\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/bottle-1811019_1920.jpg\",\"datePublished\":\"2022-01-31T08:14:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/#\\\/schema\\\/person\\\/ecf33c1b8323512588da2815912dafbd\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/#primaryimage\",\"url\":\"https:\\\/\\\/eurogip.fr\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/bottle-1811019_1920.jpg\",\"contentUrl\":\"https:\\\/\\\/eurogip.fr\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/bottle-1811019_1920.jpg\",\"width\":1917,\"height\":1033,\"caption\":\"plastic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The CJEU confirms the identification of BPA as an endocrine disruptor for health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/\",\"name\":\"Eurogip\",\"description\":\"Comprendre les risques professionnels en Europe\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eurogip.fr\\\/en\\\/#\\\/schema\\\/person\\\/ecf33c1b8323512588da2815912dafbd\",\"name\":\"Isabelle Leleu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f3cc67d25190b9c8fc03b41a3a08d1a3f65084bac3fb332e444c9f15a811b63e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f3cc67d25190b9c8fc03b41a3a08d1a3f65084bac3fb332e444c9f15a811b63e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f3cc67d25190b9c8fc03b41a3a08d1a3f65084bac3fb332e444c9f15a811b63e?s=96&d=mm&r=g\",\"caption\":\"Isabelle Leleu\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The CJEU confirms the identification of BPA as an endocrine disruptor for health - Eurogip","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/","og_locale":"en_US","og_type":"article","og_title":"The CJEU confirms the identification of BPA as an endocrine disruptor for health - Eurogip","og_description":"The Court of Justice of the European Union (CJEU) has confirmed on appeal the identification of bisphenol A (BPA) as a substance of very high concern for its endocrine disrupting properties for human health.","og_url":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/","og_site_name":"Eurogip","article_published_time":"2022-01-31T08:14:08+00:00","og_image":[{"width":1917,"height":1033,"url":"https:\/\/eurogip.fr\/wp-content\/uploads\/2022\/01\/bottle-1811019_1920.jpg","type":"image\/jpeg"}],"author":"Isabelle Leleu","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Isabelle Leleu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/#article","isPartOf":{"@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/"},"author":{"name":"Isabelle Leleu","@id":"https:\/\/eurogip.fr\/en\/#\/schema\/person\/ecf33c1b8323512588da2815912dafbd"},"headline":"The CJEU confirms the identification of BPA as an endocrine disruptor for health","datePublished":"2022-01-31T08:14:08+00:00","mainEntityOfPage":{"@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/"},"wordCount":191,"image":{"@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/#primaryimage"},"thumbnailUrl":"https:\/\/eurogip.fr\/wp-content\/uploads\/2022\/01\/bottle-1811019_1920.jpg","articleSection":["Community news"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/","url":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/","name":"The CJEU confirms the identification of BPA as an endocrine disruptor for health - Eurogip","isPartOf":{"@id":"https:\/\/eurogip.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/#primaryimage"},"image":{"@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/#primaryimage"},"thumbnailUrl":"https:\/\/eurogip.fr\/wp-content\/uploads\/2022\/01\/bottle-1811019_1920.jpg","datePublished":"2022-01-31T08:14:08+00:00","author":{"@id":"https:\/\/eurogip.fr\/en\/#\/schema\/person\/ecf33c1b8323512588da2815912dafbd"},"breadcrumb":{"@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/#primaryimage","url":"https:\/\/eurogip.fr\/wp-content\/uploads\/2022\/01\/bottle-1811019_1920.jpg","contentUrl":"https:\/\/eurogip.fr\/wp-content\/uploads\/2022\/01\/bottle-1811019_1920.jpg","width":1917,"height":1033,"caption":"plastic"},{"@type":"BreadcrumbList","@id":"https:\/\/eurogip.fr\/en\/the-cjeu-confirms-the-identification-of-bpa-as-an-endocrine-disruptor-for-health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eurogip.fr\/en\/"},{"@type":"ListItem","position":2,"name":"The CJEU confirms the identification of BPA as an endocrine disruptor for health"}]},{"@type":"WebSite","@id":"https:\/\/eurogip.fr\/en\/#website","url":"https:\/\/eurogip.fr\/en\/","name":"Eurogip","description":"Comprendre les risques professionnels en Europe","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eurogip.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/eurogip.fr\/en\/#\/schema\/person\/ecf33c1b8323512588da2815912dafbd","name":"Isabelle Leleu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f3cc67d25190b9c8fc03b41a3a08d1a3f65084bac3fb332e444c9f15a811b63e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f3cc67d25190b9c8fc03b41a3a08d1a3f65084bac3fb332e444c9f15a811b63e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f3cc67d25190b9c8fc03b41a3a08d1a3f65084bac3fb332e444c9f15a811b63e?s=96&d=mm&r=g","caption":"Isabelle Leleu"}}]}},"_links":{"self":[{"href":"https:\/\/eurogip.fr\/en\/wp-json\/wp\/v2\/posts\/29643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurogip.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurogip.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurogip.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/eurogip.fr\/en\/wp-json\/wp\/v2\/comments?post=29643"}],"version-history":[{"count":0,"href":"https:\/\/eurogip.fr\/en\/wp-json\/wp\/v2\/posts\/29643\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eurogip.fr\/en\/wp-json\/wp\/v2\/media\/29574"}],"wp:attachment":[{"href":"https:\/\/eurogip.fr\/en\/wp-json\/wp\/v2\/media?parent=29643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurogip.fr\/en\/wp-json\/wp\/v2\/categories?post=29643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}